Feb. 20, 2013
/PRNewswire/ - Oncolytics Biotech Inc.
("Oncolytics") (TSX:ONC; NASDAQ:ONCY) announced today the pricing of an underwritten public offering of 8.0 million common shares, at a public offering price of
per common share. The Company estimates that the gross proceeds from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Oncolytics, will be
. The offering is expected to close on or about
February 25, 2013
, subject to customary closing conditions.
& Co. and Wedbush PacGrow Life Sciences are acting as joint book-running managers for the offering in the U.S. and Paradigm Capital Inc. is acting as co-manager in the U.S. and book-running manager in
The Company has granted to the underwriters participating in the offering a 30-day option to purchase up to an additional 1.2 million common shares to cover over-allotments, if any.
Oncolytics intends to use the net proceeds from the offering to fund its clinical trial program, manufacturing program and for general corporate and working capital purposes.
The common shares are being offered in each of the Canadian provinces of
by way of a prospectus supplement to the Company's base shelf short form prospectus and in
the United States
pursuant to a prospectus supplement to the Company's effective shelf registration statement on Form F-10 (333-182260) previously filed with the United States Securities and Exchange Commission. Copies of the prospectus supplement and accompanying base prospectus relating to the offering may be obtained from the Securities and Exchange Commission website at
, from the System for Electronic Document Analysis and Retrieval (SEDAR) website at
or from the underwriters at:
& Co. 800 Nicollet Mall, J12S03,
Telephone: (800) 747-3924
Wedbush Securities Inc.
One Bush Street
, 17th floor,
San Francisco, CA
94104 Attn: SF Prospectus Department Phone: 415-274-6819 Fax: 415-274-6887
Before you invest, you should read the prospectus supplement and accompanying prospectus, the registration statement, and the other documents that the Company has filed with the Securities and Exchange Commission for more complete information about the Company and this offering.